TY - JOUR
T1 - Kidney Transplantation in Systemic Amyloidosis
AU - Angel-Korman, Avital
AU - Havasi, Andrea
N1 - Funding Information:
This work was supported in parts by funds provided by the Wildflower Foundation and the McCaleb Award from the Amyloidosis Center, Boston University School of Medicine, and Alan and Sandra Gerry Amyloid Research Laboratory (to A.A.-K. and A.H.).
Publisher Copyright:
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - The present review discusses current developments and outcomes of renal transplantation in systemic amyloidosis. Amyloidosis can wreak havoc on the architecture and functioning of the kidneys, leading to end-stage renal disease. In recent years, the available treatments, especially for light-chain amyloidosis but also for several of the underlying inflammatory diseases that cause amyloid A amyloidosis have expanded leading to prolonged survival albeit frequently with renal failure. At the same time, there are also increasing numbers of patients diagnosed with one of the inherited forms of amyloidosis for which currently there is no targeted treatment available and, in some cases, renal failure is unavoidable. Due to the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for the clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation. Determining eligibility criteria, as well as peritransplant and posttransplant management, requires a multidisciplinary approach with close monitoring and follow-up.
AB - The present review discusses current developments and outcomes of renal transplantation in systemic amyloidosis. Amyloidosis can wreak havoc on the architecture and functioning of the kidneys, leading to end-stage renal disease. In recent years, the available treatments, especially for light-chain amyloidosis but also for several of the underlying inflammatory diseases that cause amyloid A amyloidosis have expanded leading to prolonged survival albeit frequently with renal failure. At the same time, there are also increasing numbers of patients diagnosed with one of the inherited forms of amyloidosis for which currently there is no targeted treatment available and, in some cases, renal failure is unavoidable. Due to the complex nature of the pathophysiology and treatment of these diseases, it can be very challenging for the clinician to determine whether or not it is appropriate to refer an affected individual for kidney transplantation. Determining eligibility criteria, as well as peritransplant and posttransplant management, requires a multidisciplinary approach with close monitoring and follow-up.
UR - http://www.scopus.com/inward/record.url?scp=85091691779&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000003170
DO - 10.1097/TP.0000000000003170
M3 - Review article
C2 - 32053574
AN - SCOPUS:85091691779
SN - 0041-1337
VL - 104
SP - 2035
EP - 2047
JO - Transplantation
JF - Transplantation
IS - 10
ER -